# ViiV Healthcare: Phase 1 study terminated, 30 enrolled (HIV Infections)

**Score:** 45/100

| Field | Value |
|---|---|
| Sponsor | ViiV Healthcare |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIV |
| NCT ID | NCT06652958 |
| Phase | Phase 1 |
| Status | terminated |
| Conditions | HIV Infections |
| Intervention types | biological |
| Target enrollment | 30 |
| Site countries | United States |
| Posted | 2024-10-22 |
| Planned start | 2024-10-02 |
| Event | Terminated |
| Event date | 2026-09-09 |
| Last update posted | 2026-10-15 |

## Why this score
- Industry sponsor (buys outsourced services).
- Stopped early: budget and sites freed up.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06652958). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.